Advanced search
Publication Cover
Leukemia & Lymphoma Volume 7, 1992 - Issue 1-2
Submit an article Journal homepage
21
Views
20
CrossRef citations to date
0
Altmetric
Original Article

Beta 2 Microglobulin Level as an Indicator of Prognosis in Diffuse Large Cell Lymphoma

Agustin Avilés Departments of Hematology, Oncology Hospital, National Medical Center, I.M.S.S., México, D.F., Mexico
,
Gloria Zepeda Departments of Medical Oncology, Oncology Hospital, National Medical Center, I.M.S.S., México, D.F., Mexico
,
José C. Díaz-Maqueo Departments of Hematology, Oncology Hospital, National Medical Center, I.M.S.S., México, D.F., Mexico
,
Leticia Rodriguez Departments of Pathology, Oncology Hospital, National Medical Center, I.M.S.S., México, D.F., Mexico
,
Renaldo Guzmán Departments of Hematology, Oncology Hospital, National Medical Center, I.M.S.S., México, D.F., Mexico
,
Edna L. García Departments of Hematology, Oncology Hospital, National Medical Center, I.M.S.S., México, D.F., Mexico
&
Alejandra Talavera Departments of Hematology, Oncology Hospital, National Medical Center, I.M.S.S., México, D.F., Mexico
 show all
Pages 135-138 | Received 10 Sep 1991, Published online: 01 Jul 2009

References

  • Epelbaum R., Fanaggi D., Ben-Arie Y., et al. Survival of diffuse large cell lymphoma. Cancer 1990; 66: 1124–1129
  • Vose J. M., Armitage J. D., Weisenburger D. D., et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 1988; 6: 1838–1844
  • Coiffier B., Lepage E. Prognosis of aggressive lymphomas. A study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989; 74: 558–564
  • Aviles A., Diaz-Maqueo J. C., Rodriguez L., et al. Group risk classification of non-Hodgkin's lymphoma. Arch. Invest. Med., 21: 11–16
  • Armitage J. O., Dick F. R., Corder M. P., Garneau S. G., Platz C. E., Slymen D. J. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1982; 50: 1695–1702
  • Coiffier B., Shipp M. A., Cabanillas F., Crowther D., Armitage J. O., Canellos G. P. Report on the first workshop on prognostic factors in large-cell lymphoma. Ann Oncol. 1991; 2: 213–217
  • Swan F., Velasquez W. S., Tucker S., et al. A new serologic staging system for large-cell lymphomas based on initial beta 2 microglobulin and lactate dehydrogenase levels. J. Clin. Omol 1989; 7: 1518–1527
  • Simon R., Durrleman S., Hoppe R. T., et al. Prognostic factors for patients with diffuse large-cell or immunoblastic non-Hodgkin's lymphomas. Experience of the Non-Hodgkin's Lymphoma Pathologic Classification Project. Med. Pediatr. Oncol. 1990; 18: 89–96
  • Velasquez W. S., Jagannath S., Tucker S. L., et al. Risk classification as the basis for clinical staging of large-cell lymphoma derives from 10-year survival data. Blood 1989; 74: 552–557
  • Shimoyama M., Ota K., Kikuchi M., et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-. J. Clin. Oncol. 1988; 6: 128–141
  • Coiffier B., Gisselbrecht C., Vose J. M., et al. Prognostic factors in aggressive malignant lymphomas. Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J. Clin. Oncol. 1991; 9: 211–219
  • Hisamoto S., Shiboya H., Hoshima M., Horiuchi J. Prognostic factors in head and neck non-Hodgkin's lymphoma with special reference to serum lactic dehydrogenase and serum cooper. Acta Oncol. 1990; 29: 879–883
  • Slymer D. J., Miller T. P., Lippman S. M., et al. Immunobiologic factors predicting of clinical outcome in diffuse large-cell lymphoma. J. Clin. Oncol. 1990; 8: 986–993
  • Hoskins P., Ng U., Spinelli J. J., Klimo P., Connors J. M. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J. Clin. Oncol 1991; 9: 220–226
  • Ciampi A., Buch R. S., Gospodarowich M., Till J. E. An approach to classifying prognostic factors related to survival experience for non-Hodgkin's lymphoma patients. Cancer 1981; 47: 621–627
  • Dana B. W., Dahlberg S., Miller T. P., et al. m-BACOD treatment for intermediate and high-grade malignant lymphoma. A Southwest Oncology Group phase II trial. J. Clin. Oncol. 1990; 8: 1155–1162
  • Bethea M., Forman D. T. Beta 2 microglobulin. Its significance and clinical usefulness. Ann. Clin. Lab. Sci. 1990; 20: 163–168
  • Litman P., Swan F., Cabanillas F., et al. Prognostic value of serum beta 2 microglobulin in low-grade lymphoma. Ann Intern. Med. 1991; 114: 855–860
  • Avilés A., Diaz-Maqueo J. C., Rodriguez L., et al. Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma. Hematol. Oncol 1991; 9: 115–121
  • The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma. Cancer 1982; 49: 2112–2135
  • Avilés A., Diaz-Maqueo J. C., Torras V., Rodriguez L., Löpez V. D. Linfomas no Hodgkinianos. Resultados de la quimioterapia alterna frente a la quimioterapia secuencial. Sangre (Bare) 1990; 35: 245–249
  • Kaplan E. L., Meier P. Non paramatric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–481
  • Cox D. R. Regression models and life tables. J. Stat. Soc, 34: 187–224
  • Amlot P. L., Adinolfi M. Serum beta 2 microglobulin and its prognostic value in lymphoma. Eur. J. Cancer 1979; 15: 791–796
  • Schneider R. J., Seibert K., Passe S., et al. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer 1980; 46: 139–143

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.